- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
European Approval for Pfizer-Wyeth Deal
20 July 2009
Pfizer's pending acquisition of Wyeth has been approved by the European Commission.
However, despite this step forward, final completion of the deal still remains subject to a number of factors; expiration of the waiting period under the US Hart-Scott-Rodino Antitrust Improvements Act, various other governmental and regulatory approvals and, perhaps most importantly, approval by Wyeth stockholders.
In a press release, Amy Schulman, senior vice president and general counsel at Pfizer said: "We are pleased to have achieved another significant milestone for the pending acquisition with the EC's approval of the transaction."
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
